CSPC Pharmaceutical Group and AstraZeneca reach a licensing cooperation of more than US$5 billion
On June 13, AstraZeneca announced a strategic research collaboration with CSPC Pharmaceutical Group. According to the agreement, AstraZeneca and CSPC Pharmaceutical Group agreed to discover and develop preclinical drug candidates with potential for treating multiple chronic diseases for multiple targets, including a preclinical small molecule oral therapy for immune diseases. CSPC Pharmaceutical Group will receive an advance payment of US$110 million and is eligible for potential R&D milestone payments of up to US$1.62 billion and potential sales milestone payments of up to US$3.6 billion, as well as potential single-digit sales commissions based on the annual net sales of the relevant products. From this point of view, through licensing cooperation, CSPC Pharmaceutical Group is expected to receive more than US$5 billion.